Premium
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
Author(s) -
Jones Jeffrey A.,
Hillmen Peter,
Coutre Steven,
Tam Constantine,
Furman Richard R.,
Barr Paul M.,
Schuster Stephen J.,
Kipps Thomas J.,
Flinn Ian W.,
Jaeger Ulrich,
Burger Jan A.,
Cheng Mei,
Ninomoto Joi,
James Danelle F.,
Byrd John C.,
O'Brien Susan M.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14660
Subject(s) - ibrutinib , medicine , discontinuation , concomitant , chronic lymphocytic leukemia , hematology , leukemia
Summary Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia ( CLL ) patients treated with ibrutinib. We analysed data from two studies of single‐agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib‐treated patients, concomitant anticoagulation (11%) or antiplatelet use (34%) was common, but major bleeding was infrequent (2%). Bleeding events were primarily grade 1, and infrequently (1%) led to discontinuation. Among 175 patients receiving concomitant anticoagulant or antiplatelet agents, 5 had major bleeding events (3%). These events were typically observed in conjunction with other factors, such as coexisting medical conditions and/or concurrent medications.